Department of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, Liaoning, China.
Department of Pharmaceutical Sciences, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, Liaoning, China.
Arch Gynecol Obstet. 2021 Jan;303(1):27-36. doi: 10.1007/s00404-020-05808-8. Epub 2020 Sep 28.
The efficacy of progesterone supplementation in the treatment of threatened miscarriage is controversial. This meta-analysis was to evaluate the correlation between progesterone and improving pregnancy outcomes in women with threatened miscarriage.
We searched PubMed, EMBASE, and the Cochrane Library for relevant randomized controlled trials (RCTs) to demonstrate the efficacy of progesterone on the threatened miscarriage pregnancy. The outcomes were miscarriage, preterm birth, and live birth.
Nine RCTs comparing 4907 patients were included in this study. Compared with placebo or no treatment, progesterone supplementation had a relationship with a reduction in the rate of miscarriage [RR 0.70 95% Cl (0.52, 0.94)]. There was no significant difference between progesterone supplementation and placebo or no treatment in preterm birth [RR 0.87 95% Cl (0.52, 1.47) and live birth (RR 1.02 95% Cl (0.98, 1.07)].
Progesterone supplementation did not significantly improve the incidence of preterm and live birth, so progesterone treatment of threatened miscarriage may be unhelpful.
孕激素补充治疗先兆流产的疗效存在争议。本荟萃分析旨在评估孕激素与改善先兆流产患者妊娠结局的相关性。
我们检索了 PubMed、EMBASE 和 Cochrane 图书馆中关于孕激素治疗先兆流产的随机对照试验（RCT）。结局指标为流产、早产和活产。
本研究纳入了 9 项 RCT，共 4907 例患者。与安慰剂或空白对照相比，孕激素补充治疗与降低流产率相关[RR 0.70，95%CI（0.52，0.94）]。孕激素补充治疗与安慰剂或空白对照在早产[RR 0.87，95%CI（0.52，1.47）]和活产[RR 1.02，95%CI（0.98，1.07）]方面的差异均无统计学意义。
孕激素补充治疗并未显著降低早产和活产的发生率，因此孕激素治疗先兆流产可能无益。
